Tags

Type your tag names separated by a space and hit enter

Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
Anticancer Res. 2010 Feb; 30(2):547-52.AR

Abstract

BACKGROUND

We have previously shown that the receptor tyrosine kinases, KIT and PDGFRalpha, are expressed on ESFT cell lines, and that imatinib induces dose-dependent apoptosis (1). We conducted a Phase II trial to evaluate the effectiveness of imatinib for patients with recurrent ESFT or DSRCT expressing KIT and/or PDGFRalpha.

PATIENTS AND METHODS

Patients were selected for tumor immunohisto-chemical expression > or =2+/4+ for KIT or PDGFRalpha. Imatinib was administered orally 400 mg twice/day for 28 days/course. Primary endpoint was response.

RESULTS

Seven patients were enrolled and evaluated. One patient with 3+/4+ PDGFRalpha and 3+/4+ KIT expression had a partial response through 8 courses. 4 patients had progression after 1 cycle. Two patients were not evaluable due to one early death and one refusing treatment.

CONCLUSION

This study intended to enrich for molecular factors that potentially predict response. Given the poor prognosis with recurrent ESFT, further studies with other novel KIT and PDGFRalpha inhibitors are needed.

Authors+Show Affiliations

Department of Medical Oncology, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA. jchao@coh.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20332468

Citation

Chao, Joseph, et al. "Phase II Clinical Trial of Imatinib Mesylate in Therapy of KIT And/or PDGFRalpha-expressing Ewing Sarcoma Family of Tumors and Desmoplastic Small Round Cell Tumors." Anticancer Research, vol. 30, no. 2, 2010, pp. 547-52.
Chao J, Budd GT, Chu P, et al. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res. 2010;30(2):547-52.
Chao, J., Budd, G. T., Chu, P., Frankel, P., Garcia, D., Junqueira, M., Loera, S., Somlo, G., Sato, J., & Chow, W. A. (2010). Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Research, 30(2), 547-52.
Chao J, et al. Phase II Clinical Trial of Imatinib Mesylate in Therapy of KIT And/or PDGFRalpha-expressing Ewing Sarcoma Family of Tumors and Desmoplastic Small Round Cell Tumors. Anticancer Res. 2010;30(2):547-52. PubMed PMID: 20332468.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. AU - Chao,Joseph, AU - Budd,G Thomas, AU - Chu,Peiguo, AU - Frankel,Paul, AU - Garcia,Dolores, AU - Junqueira,Maribel, AU - Loera,Sofia, AU - Somlo,George, AU - Sato,Judith, AU - Chow,Warren A, PY - 2010/3/25/entrez PY - 2010/3/25/pubmed PY - 2010/5/5/medline SP - 547 EP - 52 JF - Anticancer research JO - Anticancer Res. VL - 30 IS - 2 N2 - BACKGROUND: We have previously shown that the receptor tyrosine kinases, KIT and PDGFRalpha, are expressed on ESFT cell lines, and that imatinib induces dose-dependent apoptosis (1). We conducted a Phase II trial to evaluate the effectiveness of imatinib for patients with recurrent ESFT or DSRCT expressing KIT and/or PDGFRalpha. PATIENTS AND METHODS: Patients were selected for tumor immunohisto-chemical expression > or =2+/4+ for KIT or PDGFRalpha. Imatinib was administered orally 400 mg twice/day for 28 days/course. Primary endpoint was response. RESULTS: Seven patients were enrolled and evaluated. One patient with 3+/4+ PDGFRalpha and 3+/4+ KIT expression had a partial response through 8 courses. 4 patients had progression after 1 cycle. Two patients were not evaluable due to one early death and one refusing treatment. CONCLUSION: This study intended to enrich for molecular factors that potentially predict response. Given the poor prognosis with recurrent ESFT, further studies with other novel KIT and PDGFRalpha inhibitors are needed. SN - 1791-7530 UR - https://www.unboundmedicine.com/medline/citation/20332468/Phase_II_clinical_trial_of_imatinib_mesylate_in_therapy_of_KIT_and/or_PDGFRalpha_expressing_Ewing_sarcoma_family_of_tumors_and_desmoplastic_small_round_cell_tumors_ L2 - http://ar.iiarjournals.org/cgi/pmidlookup?view=long&pmid=20332468 DB - PRIME DP - Unbound Medicine ER -